item management s discussion and analysis of financial condition and results of operations this review contains management s discussion of the company s operational results and financial condition and should be read in conjunction with the accompanying financial statements 
overview medimmune commenced operations in april and  through  revenue was generated solely from research and development agreements and research grants 
in  contract revenues rose substantially and the company began selling its first product  cytogam  to an exclusive distributor 
in december  the company reacquired the cytogam marketing rights from its distributor and launched an expanded marketing program for this product through its own sales force 
on january   the company s second product  respigam was licensed for marketing by the us food and drug administration fda for the prevention of serious lower respiratory tract infection caused by rsv in children under months of age with bpd or a history of prematurity 
ahp s wyeth lederle vaccines and pediatrics sales force co promotes respigam in the united states 
because of the seasonal nature of rsv  limited sales  if any  are expected during the second and third quarters 
to date  product sales have not produced sufficient revenues to cover the company s operating expenses 
consequently  the company has experienced substantial operating losses 
while results may vary significantly from quarter to quarter  the company does not expect to be profitable for the year at least through results of operations compared to the increase in product sales for the year ended december  as compared to the year ended december  is due to the commencement of sales of respigam in and a increase in cytogam sales 
respigam sales were million in  of which million were generated in the fourth quarter 
cytogam product sales increased to million from million in due primarily to increased units sold 
cytogam product sales were reduced by a million reserve in the third quarter for trade receivables due from a pharmaceutical wholesaler which filed chapter bankruptcy in august although the company markets directly to hospitals and physicians  the company sells its products through a limited number of pharmaceutical wholesalers and a similar event with another wholesaler could adversely affect operating income 
the level of future product sales will be dependent on several factors  including  but not limited to  the timing and extent of future regulatory approvals of the company s products and product candidates  availability of finished product inventory  approval and commercialization of competitive products and the degree of acceptance of the company s products in the marketplace 
currently  respigam finished product inventory is in short supply  and no assurances can be given that an adequate supply will be available to meet demand 
contract revenue decreased to million in from million in  reflecting the completion of milestone and research funding payments under the company s strategic alliance with ahp  formerly american cyanamid company 
under the terms of the alliance  the company and ahp will share in the profits or losses of respigam  reimbursements or payments under this arrangement are deducted from or added to operating expenses 
the level of contract revenues in future periods will depend primarily upon the extent to which the company enters into other collaborative contractual arrangements  if any 
cost of sales increased to million in from million in  due to the initiation of sales of respigam in the gross margins for of improved over s margins of reflecting the addition of respigam as well as a reduction in the royalty rate due to connaught for cytogam  effective for the fourth quarter of the company s products are manufactured by third parties and future per unit cost of sales could increase if the company is unable to negotiate favorable pricing 
the company is currently constructing its own manufacturing facility intended for some portion of the production of its two approved products as well as other product candidates 
this facility is not expected to be completed until and then is subject to inspection and approval by the fda 
cost of sales could be impacted by the potential production in this facility 
research  development and clinical spending was million in compared to million in  reflecting increased expenditures of over million for medi rsv monoclonal antibody clinical studies  including the start of a  patient phase clinical trial in the fourth quarter of this increase was offset by a decrease in clinical spending for respigam  for which two phase trials were completed in mid and licensing was received from the fda in january the level of the company s total research and development expenses in future periods will fluctuate depending on the extent of clinical trial spending 
the company expects clinical trial expenses for medi to remain high through the first half of selling  administrative and general expenses increased to million in from million in  reflecting primarily the launch of respigam in approximately additional sales and marketing personnel have been hired since september   primarily in  to staff for the launch of respigam  resulting in an increase of over million in salaries  commissions  recruiting  travel and related costs 
an additional million was spent on marketing and selling programs for the launch of respigam in sales detailing costs to the company s corporate partner for respigam  ahp  approximated million in and none in offsetting the increased costs in was a million reimbursement from ahp of their share of the product line loss on respigam for the year  calculated under the terms of the strategic alliance 
in and future years  ahp s share of respigam s potential profits will result in an increase to selling expenses 
general and administrative expenses increased by million reflecting increased headcount and legal and other costs associated with the new manufacturing facility 
in december  the company and connaught entered into an amendment to the agreement signed in in which the company reacquired the rights to market cytogam 
in connection with this amendment  the company made a lump sum payment of million to connaught in the first half of upon completion of certain modifications to connaught s filling and packaging facility 
the million charge was expensed as other operating expenses in interest income increased to million in compared to million in the increase reflects the proceeds from the company s equity and convertible debt offerings in  resulting in higher cash balances available for investment  partially offset by a decrease in interest rates which lowered the overall portfolio yield 
interest expense increased to million in from million in  reflecting interest on the convertible subordinated notes issued in july interest expense in is net of million of interest capitalized against the new manufacturing facility and the pilot plant expansion 
the net loss of million  or per common share  compared to a net loss of million  or per common share 
shares used in computing loss per share were million and million  respectively 
the company does not believe that inflation had a material effect on its financial statements 
these results were consistent with the company s objectives for the year and with the continued development of its immunotherapeutic and vaccine products 
the factors affecting results may continue to affect near term financial results 
compared to revenues in were million compared to million in sales of cytogam increased to million in from million in  reflecting a increase in units sold as well as the impact of two price increases since july  contract revenues increased to million from million in  primarily reflecting funding provided under the company s strategic alliance with ahp 
cost of sales for cytogam rose to million in from million in  reflecting the increase in unit volume and an increase in product unit costs  which include the addition of a viral inactivation process  increased unit costs of plasma paste and increased costs for finished product acquired from a supplier 
research  development and clinical spending was million in compared to million in  reflecting a research license payment of million to biotransplant  incorporated bti for bti  and increased expenditures for respigam and medi rsv monoclonal antibody clinical studies 
selling  administrative and general expenses increased to million in from million in  reflecting increased marketing expenditures for respigam  a million charge recorded in the fourth quarter in connection with the settlement of the securities class action lawsuit that had been filed against the company  and a million charge recorded in the fourth quarter relating to certain expenditures associated with preparations for the construction of a manufacturing facility 
in december  the company entered into a stipulation of settlement resolving a pending securities class action lawsuit against the company 
the company recorded a charge of approximately million in in connection with the settlement 
the company s insurers contributed the remaining million in  for a total settlement of million 
other operating expenses include the charge for restructuring of the connaught agreement as discussed above 
interest income of million was earned in the year ended december  compared to million in  reflecting an increase in interest rates which improved overall portfolio yield 
interest expense of million was incurred in both and the net loss of million  or per common share  compared to a net loss of million  or per common share 
shares used in computing loss per share were million and million  respectively 
liquidity and capital resources cash and marketable securities were million at year end compared to million at year end 
working capital was million at year end versus million at year end 
net cash used in operating activities was million compared to million used in and million used in the cash outflow from operations in reflected the net loss adjusted for depreciation and amortization and working capital changes 
working capital changes include a million increase in trade and contract receivables due to significant fourth quarter sales of respigam  a million increase in accounts payable and accrued expenses  reflecting accrued costs associated with the medi phase clinical trial  accrued manufacturing costs for production of the company s two products  and accrued marketing and selling costs  including commissions  and a million increase in accrued interest reflecting interest due on the convertible subordinated notes  paid january the cash outflow from operations in reflected the net loss adjusted for depreciation and amortization and working capital changes  including a million decrease in trade and contract receivables and a million increase in accrued expenses primarily related to the amendment to the connaught agreement 
cash flows from financing activities were million in compared to million in in february  the company completed a public offering of million shares of common stock resulting in net proceeds of million and in july  the company completed a private placement of million aggregate principal amount of convertible subordinated notes due for net proceeds of million 
additionally  the company received million of proceeds from state government loans in connection with the financing of its new manufacturing facility 
in  the company received million from a private placement of the company s common stock with a group of foreign institutional investors  million from a sale of the company s common stock to baxter in connection with an alliance entered into in june  and million through a sale of the company s common stock to ahp 
capital expenditures in were million compared to million in the expenditures include million for the design and construction of the company s new manufacturing facility located in frederick  maryland and the expansion of the pilot plant at the gaithersburg headquarters 
additional expenditures were for land  laboratory equipment and administrative expansion 
the expenditures included expenditures for additional laboratory and office equipment as well as initial design work for the new manufacturing facility 
capital expenditures in are expected to approximate million  due mostly to the construction of the manufacturing facility and the expansion of the development pilot plant 
these two projects are anticipated to cost a total of million and are intended to be financed from the proceeds of the convertible debt offering and state and local loans totaling million 
the company entered into an engineering  procurement  construction and validation services agreement with fluor daniel to design and construct the manufacturing facility in frederick  maryland 
the agreement provides for an early completion bonus to fluor daniel if the facility is completed ahead of schedule or liquidated damages paid to the company for certain delays 
the facility  expected to employ to people  will provide capacity for the company s immune globulin products and monoclonal antibody product candidates 
the facility is expected to be completed and initial production commenced during there can be no assurance that when the facility is constructed appropriate regulatory approvals will be obtained to enable the use of the facility for production of the company s products or product candidates 
the company s pilot plant expansion is intended to support the further production of materials for phase clinical trials and market entry requirements  if needed  for medi in addition  the company is obligated in to provide million in funding for various clinical trials  research and development and license agreements with certain institutions 
the company s existing funds  together with funds contemplated to be generated from product sales and investment income are expected to provide sufficient liquidity to meet the anticipated needs of the business for at least the next months  absent the occurrence of any unforeseen events 

